Literature DB >> 9973183

Processing of adenosine receptor agonists in rat and human whole blood.

B Pavan1, A P IJzerman.   

Abstract

A stability study of adenosine receptor agonists in rat and human whole blood was performed. The compounds were incubated at 37 degrees in fresh blood, and aliquots of the incubation mixture were hemolyzed at regular time intervals and analyzed with HPLC. N6-cyclopentyladenosine (CPA) and N6-cyclobutyladenosine (CBA) were degraded, whereas N6-cyclohexyladenosine, N6-cycloheptyladenosine and N6-sulfophenyladenosine were not. 2-Chloroadenosine had a half-life very similar to that of CPA. However, the 2'-, 3'-, and 5'-deoxyribose derivatives of CPA remained intact. The nucleoside transport inhibitor nitrobenzylthioinosine attenuated CBA and CPA metabolism in rat blood as did the inhibitor of adenosine deaminase erythro-9-(2-hydroxy-3-nonyl)adenine, albeit at relatively high concentrations. Complete blockade of CBA and CPA degradation was achieved by a preincubation of rat and human blood with the adenosine kinase (AK) inhibitor 5'-amino-5'-deoxyadenosine. We conclude that the two adenosine analogues are metabolized by AK both in rat and in human whole blood.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9973183     DOI: 10.1016/s0006-2952(98)00270-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

1.  Synthesis and study of 5'-ester prodrugs of N6-cyclopentyladenosine, a selective A1 receptor agonist.

Authors:  A Dalpiaz; A Scatturin; E Menegatti; F Bortolotti; B Pavan; C Biondi; E Durini; S Manfredini
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

Review 2.  International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.

Authors:  B B Fredholm; A P IJzerman; K A Jacobson; K N Klotz; J Linden
Journal:  Pharmacol Rev       Date:  2001-12       Impact factor: 18.923

3.  The effect of adenosine deaminase inhibition on the A1 adenosinergic and M2 muscarinergic control of contractility in eu- and hyperthyroid guinea pig atria.

Authors:  Krisztian Pak; Judit Zsuga; Zita Kepes; Tamas Erdei; Balazs Varga; Bela Juhasz; Andras Jozsef Szentmiklosi; Rudolf Gesztelyi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-04-16       Impact factor: 3.000

4.  Accuracy and Precision of the Receptorial Responsiveness Method (RRM) in the Quantification of A1 Adenosine Receptor Agonists.

Authors:  Adrienn Monika Szabo; Gabor Viczjan; Tamas Erdei; Ildiko Simon; Rita Kiss; Andras Jozsef Szentmiklosi; Bela Juhasz; Csaba Papp; Judit Zsuga; Akos Pinter; Zoltan Szilvassy; Rudolf Gesztelyi
Journal:  Int J Mol Sci       Date:  2019-12-12       Impact factor: 5.923

5.  FSCPX, a Chemical Widely Used as an Irreversible A₁ Adenosine Receptor Antagonist, Modifies the Effect of NBTI, a Nucleoside Transport Inhibitor, by Reducing the Interstitial Adenosine Level in the Guinea Pig Atrium.

Authors:  Tamas Erdei; Adrienn Monika Szabo; Nora Lampe; Katalin Szabo; Rita Kiss; Judit Zsuga; Csaba Papp; Akos Pinter; Andras Jozsef Szentmiklosi; Zoltan Szilvassy; Bela Juhasz; Rudolf Gesztelyi
Journal:  Molecules       Date:  2018-08-30       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.